Sector
PharmaceuticalsOpen
₹192.84Prev. Close
₹191.84Turnover(Lac.)
₹464.1Day's High
₹207.72Day's Low
₹192.8452 Week's High
₹39852 Week's Low
₹154.5Book Value
₹69.66Face Value
₹1Mkt Cap (₹ Cr.)
1,666.21P/E
25.51EPS
7.52Divi. Yield
0.21Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 37.05 | 8.47 | 8.47 | 8.47 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 533.45 | 486.63 | 485.3 | 419.76 |
Net Worth | 570.5 | 495.1 | 493.77 | 428.23 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 563.17 | 411.94 | 462.67 | 438.12 |
yoy growth (%) | 36.71 | -10.96 | 5.6 | -27.36 |
Raw materials | -339.99 | -246.36 | -289.89 | -295.84 |
As % of sales | 60.37 | 59.8 | 62.65 | 67.52 |
Employee costs | -41.17 | -39.35 | -32.8 | -26.92 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 91.11 | 50.75 | 60.34 | 41.58 |
Depreciation | -22.28 | -22.06 | -19.89 | -19.17 |
Tax paid | -30.15 | -18.06 | -19.89 | -5.96 |
Working capital | 60.27 | 35.89 | 36.48 | -52.78 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 36.71 | -10.96 | 5.6 | -27.36 |
Op profit growth | 51.54 | -14.37 | 24.78 | -16.14 |
EBIT growth | 62.43 | -16.96 | 32.87 | -22.21 |
Net profit growth | 86.5 | -19.19 | 13.58 | -14.46 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 709.26 | 522.05 | 519.87 | 563.18 | 411.95 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 709.26 | 522.05 | 519.87 | 563.18 | 411.95 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.46 | 4.91 | 5.2 | 3.45 | 5.11 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,614 | 122.93 | 3,87,276.66 | 1,181.05 | 0.84 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,568.7 | 71.3 | 1,47,802.29 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,461.75 | 25.37 | 1,18,061.19 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,059 | 56.75 | 1,03,513.97 | 485 | 0.92 | 2,330 | 222.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,140.1 | 18.33 | 95,026.5 | 849.4 | 0.7 | 4,997.8 | 322.46 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
P Ramesh Babu
Independent Director
P Sarath Kumar
Independent Director
Thummala Neelaveni
Independent Director
Shravan Kudaravalli
Independent Director
Sarvepalli Srinivas
Executive Director
Vamsi Krishna Potluri
Company Sec. & Compli. Officer
Thirumalesh Tumma
Independent Director
Trilok Potluri.
Non Executive Director
Sunkara Venkata Satya Shiva Prasad
Independent Director
G Suresh Kumar
Independent Director
Shanti Sree Bolleni
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by SMS Pharmaceuticals Ltd
Summary
SMS Pharmaceuticals Limited was incorporated in December, 1987. The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates. Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. Its business activity is a single primary business segment of Bulk Drugs. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities.During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24.During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s. VKT Pharma Private Limited. With this the said company has become an associate company. The project of the said associate company is in final stage and at the verge of completion and operations are yet to be commenced. The Company has not having any subsidiaries.During the year 2015-16, the Company had sub divided the face value of share of Rs 10/- each into face value of Rs 1/- of each with record date of 18th December 2015.During FY 2015-16, the Board has approved the Draft Scheme of Arrangement for Demerger of Semi Regulated Units (Unit - I, IV & V) along with other Assets to transfer the same to SMS Lifesciences India Limited (Resulting Company), wit
Read More
The SMS Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹196.83 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Pharmaceuticals Ltd is ₹1666.21 Cr. as of 06 Mar ‘25
The PE and PB ratios of SMS Pharmaceuticals Ltd is 25.51 and 2.72 as of 06 Mar ‘25
The 52-week high/low is the highest and lowest price at which a SMS Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of SMS Pharmaceuticals Ltd is ₹154.5 and ₹398 as of 06 Mar ‘25
SMS Pharmaceuticals Ltd's CAGR for 5 Years at 39.28%, 3 Years at 28.28%, 1 Year at 8.60%, 6 Month at -41.16%, 3 Month at -23.40% and 1 Month at -8.94%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.